Iqvia Holdings Inc (NYSE:IQV) Stock Position Cut by Boston Advisors LLC

Boston Advisors LLC reduced its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 0.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 23,292 shares of the medical research company’s stock after selling 98 shares during the period. Boston Advisors LLC’s holdings in Iqvia were worth $3,479,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Foundations Investment Advisors LLC increased its stake in shares of Iqvia by 23.6% during the second quarter. Foundations Investment Advisors LLC now owns 6,630 shares of the medical research company’s stock worth $1,070,000 after purchasing an additional 1,266 shares in the last quarter. WINTON GROUP Ltd grew its stake in Iqvia by 5.2% during the 2nd quarter. WINTON GROUP Ltd now owns 8,869 shares of the medical research company’s stock valued at $1,427,000 after acquiring an additional 435 shares in the last quarter. Chesley Taft & Associates LLC grew its stake in Iqvia by 6.6% during the 2nd quarter. Chesley Taft & Associates LLC now owns 6,055 shares of the medical research company’s stock valued at $974,000 after acquiring an additional 375 shares in the last quarter. Zweig DiMenna Associates LLC purchased a new stake in Iqvia during the 2nd quarter valued at about $20,207,000. Finally, Valeo Financial Advisors LLC grew its stake in Iqvia by 23.3% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,050 shares of the medical research company’s stock valued at $330,000 after acquiring an additional 387 shares in the last quarter. Institutional investors and hedge funds own 90.06% of the company’s stock.

Several research firms have recently weighed in on IQV. Wolfe Research raised shares of Iqvia from a “peer perform” rating to an “outperform” rating in a research note on Thursday, November 14th. ValuEngine cut shares of Iqvia from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Three analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $166.46.

Shares of NYSE IQV traded up $1.80 during mid-day trading on Wednesday, reaching $145.14. The company had a trading volume of 696,952 shares, compared to its average volume of 1,287,125. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 1.85. The firm has a 50 day simple moving average of $144.38 and a two-hundred day simple moving average of $149.27. The stock has a market cap of $28.33 billion, a P/E ratio of 28.35, a PEG ratio of 1.57 and a beta of 0.88. Iqvia Holdings Inc has a 52-week low of $104.90 and a 52-week high of $164.13.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $1.60 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.57 by $0.03. Iqvia had a net margin of 2.24% and a return on equity of 16.95%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.76 billion. During the same period last year, the firm posted $1.42 EPS. Iqvia’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, equities analysts expect that Iqvia Holdings Inc will post 5.9 EPS for the current year.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: What Are Cryptocurrencies?

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.